The cannabis plant, with its complex composition containing over 100 different cannabinoids, has been the subject of extensive medical research. While the more prominent cannabinoids like THC and CBD often take center stage,  research has been expanding its focus to the properties of minor cannabinoids. One lesser-known but significant player in this botanical ensemble is Cannabigerol. CBG is the central biosynthetic precursor to many cannabinoids, often referenced as the “mother of all cannabinoids.” Cannabigerolic acid (CBGA), the precursor CBG, was isolated and characterized by R. Mechoulan and Y. Gaoni in 1965. CBG interacts with our endocannabinoid system as a  weak antagonist of both CB1 and CB2, and also interacts with TRPV receptors and 5HT1A.  Furthermore, in vitro and in vivo studies have shown it modulates immune response by influencing IL-6 alpha-TNF metabolisms. CBG is a non-psychotropic cannabis constituent and, therefore, generally considered a safe phytocannabinoid. 

The therapeutic potential of CBG is a growing area of interest and offers hope for various health conditions, including pain, epilepsy, anxiety, and cancer. The body of research includes studies on anti-aging, analgesic, neuroprotective, anti-bacterial, anti-cancer, antidepressant, anti-inflammatory and blood pressure-lowering properties.

CBG has shown anti-inflammatory effects on colitis and inflammatory bowel disease models, as well as stimulatory effects on the feeding behaviors of mice, indicating great potential to help with inflammatory digestive system disorders.  It has also shown anti-inflammatory properties in rheumatoid arthritis. Research has demonstrated modulatory effects on immunological responses involving IL-6 alpha-TNFas, opening novel possibilities for dealing with autoimmune diseases.

CBG also exerts analgesic properties in different types of pain using diverse mechanisms. Regarding our nervous system, CBG combined with CBD has been shown to reduce neuroinflammation, and research also indicates neuroprotective properties. CBG has demonstrated anticancer properties in basic research models encompassing breast cancer, glioblastoma and melanoma. Additionally, topical applications of CBG hold promise for various skin conditions.

In conclusion, CBG is emerging as a valuable compound in the realm of cannabis. As research continues to uncover its diverse capabilities, CBG could become a valuable tool for addressing a wide range of health concerns. However, it’s essential to emphasize that consulting a healthcare professional is crucial before considering CBG for any specific medical condition. Keep an eye on the evolving landscape of cannabinoids and their therapeutic potential as exciting discoveries await.

References:

• Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans. Front Microbiol. 2021 Apr 22;12:656471. doi: 10.3389/fmicb.2021.656471. PMID: 33967995; PMCID: PMC8100047.
• Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., De Petrocellis, L., Buono, L., Orlando, P., Izzo, A. A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12), 2787–2797. https://doi.org/10.1093/carcin/bgu205.
• Fleisher-Berkovich S, Ventura Y, Amoyal M, Dahan A, Feinshtein V, Alfahel L, Israelson A, Bernstein N, Gorelick J, Ben-Shabat S. Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. Biomolecules. 2023 Feb 16;13(2):376. doi: 10.3390/biom13020376. PMID: 36830745; PMCID: PMC9953076.
• Lah TT, Novak M, Pena Almidon MA, Marinelli O, Žvar Baškovič B, Majc B, Mlinar M, Bošnjak R, Breznik B, Zomer R, Nabissi M. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells. 2021 Feb 5;10(2):340. doi: 10.3390/cells10020340. PMID: 33562819; PMCID: PMC7914500.
• Lowin T, Tigges-Perez MS, Constant E, Pongratz G. Anti-Inflammatory Effects of Cannabigerol in Rheumatoid Arthritis Synovial Fibroblasts and Peripheral Blood Mononuclear Cell Cultures Are Partly Mediated by TRPA1. Int J Mol Sci. 2023 Jan 3;24(1):855. doi: 10.3390/ijms24010855. PMID: 36614296; PMCID: PMC9820932.
• Mammana S, Cavalli E, Gugliandolo A, Silvestro S, Pollastro F, Bramanti P, Mazzon E. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina (Kaunas). 2019 Nov 18;55(11):747. doi: 10.3390/medicina55110747. PMID: 31752240; PMCID: PMC6915685.
• Mechanoulam, R., Shani, A., Edery, H., & Grunfeld, Y. (1970). Chemical basis of hashish activity. Science, 169(3945), 611-2. doi: 10.1126/science.169.3945.611.
• Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero Callado C, Vincenzi F, Cas
• Perez E, Fernandez JR, Fitzgerald C, Rouzard K, Tamura M, Savile C. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. Molecules. 2022 Jan 13;27(2):491. doi: 10.3390/molecules27020491. PMID: 35056807; PMCID: PMC8778347.
• Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., & Sexton, M. (2022). Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis and Cannabinoid Research. http://doi.org/10.1089/can.2021.0058.
• Sepulveda DE, Morris DP, Raup-Konsavage WM, Sun D, Vrana KE, Graziane NM. Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. Eur J Pain. 2022 Oct;26(9):1950-1966. doi: 10.1002/ejp.2016. Epub 2022 Aug 4. PMID: 35899583.
• Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z. PMID: 25252936; PMCID: PMC4322067.
• Valeri A, Chiricosta L, Gugliandolo A, Pollastro F, Mazzon E. Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome. Pharmaceuticals (Basel). 2022 Jan 19;15(2):117. doi: 10.3390/ph15020117. PMID: 35215230; PMCID: PMC8875351.
• Viereckl MJ, Krutsinger K, Apawu A, Gu J, Cardona B, Barratt D, Han Y. Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways. Biomolecules. 2022 Jun 20;12(6):854. doi: 10.3390/biom12060854. PMID: 35740979; PMCID: PMC9221388.
• Wen Y, Wang Z, Zhang R, Zhu Y, Lin G, Li R, Zhang J. The antinociceptive activity and mechanism of action of cannabigerol. Biomed Pharmacother. 2023 Feb;158:114163. doi: 10.1016/j.biopha.2022.114163. Epub 2023 Jan 4. PMID: 36916438.